We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Shimadzu Medical Systems

Manufactures analytical instruments, testing and measuring instruments and diagnostic imaging systems read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Proline-Specific Peptidase Activities in Plasma of Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 16 Mar 2022
Print article
Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)
Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can elicit a protracted pneumonitis, but also kidney, cardiovascular and neurological complications and thromboembolic phenomena of unclear pathogenesis.

These COVID-19 patients experience several features of dysregulated immune system observed in sepsis. The activity of proline-specific peptidases in plasma of COVID-19 hospitalized patients has been investigated. The peptidases studied were dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxpeptidase (PRCP).

Medical Biochemists at the University of Antwerp (Antwerp, Belgium) and their colleagues collected heparin plasma samples from 56 hospitalized patients with laboratory-confirmed (PCR test) COVID-19 shortly after hospital admission (=baseline, 1 to 5 days after hospital admission) and thereafter at irregular time points until discharge. Additionally, plasma was taken from a control group of 32 healthy volunteers.

The scientists measured DPP4 activity colorimetrically using the substrate Gly-Pro-pNA. FAP and PREP activity was measured fluorometrically using Z-Gly-Pro-AMC in a combined FAP/PREP assay. PRCP activity was determined by measuring the hydrolysis of Z-Pro-Phe by use of a reversed-phase high-performance liquid chromatography technique. The enzymatically formed Z-Pro was tracked by its UV absorbance at 210 nm after separation on a Shimadzu HPLC apparatus (Kyoto, Japan).

The investigators reported that compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge.

The authors concluded that a similar pattern in the proline-specific peptidase activities in COVID-19 patients compared with patients experiencing septic shock: decreased DPP4 and FAP activity and elevated PREP activity. The study was published on March 10, 2022 in the journal Clinica Chimica Acta.

Related Links:
University of Antwerp 
Shimadzu 

Gold Supplier
All-in-One Solution for All Molecular Testing
STARlet-AIOS
New
Electrolyte Analyzer
CARELYTE A-Series
New
Automated R-AST Solution
Radian BC
New
Platinum Supplier
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.